🇺🇸 FDA
Patent

US 9730962

Modalities for the treatment of degenerative diseases of the retina

granted A61KA61K35/12A61K35/30

Quick answer

US patent 9730962 (Modalities for the treatment of degenerative diseases of the retina) held by Astellas Institute for Regenerative Medicine expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Astellas Institute for Regenerative Medicine
Grant date
Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
9
CPC classes
A61K, A61K35/12, A61K35/30, A61K35/44, A61K9/0048